The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine; Merck
Research Funding - JJ Innovative Medicine
Travel, Accommodations, Expenses - JJ Innovative Medicine
Treatment patterns with intravesical bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC): A real-world data analysis.
 
Ran Sun
Employment - JJ Innovative Medicine
 
Bolan Linghu
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Robert A. Somer
Employment - JJ Innovative Medicine; JJ Innovative Medicine (I)
Stock and Other Ownership Interests - JJ Innovative Medicine; JJ Innovative Medicine (I)
Other Relationship - JJ Innovative Medicine; JJ Innovative Medicine (I)
 
Shalaka Hampras
No Relationships to Disclose
 
Sumeet Kaur Bhanvadia
Employment - JJ Innovative Medicine
Leadership - Advantage Healthcare Services (I); Care Partners (I)
Stock and Other Ownership Interests - JJ Innovative Medicine
Speakers' Bureau - JJ Innovative Medicine (I)
Other Relationship - JJ Innovative Medicine (I)
 
Emily Scherer
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Joel Greshock
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Hussein Sweiti
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - FGFR Tyrosine Kinase Inhibitors For the Treatment Of Advanced Solid Tumors